RxDoctor Payments Data

Michael Carlucci, MD

Internal Medicine · Jamesburg, NJNPI 1194925750

Payments from drug & device makers

$121in general payments, 2019–2025

Across 7 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$32
  • GSK$17
  • Esperion Therapeutics, Inc.$17
  • Daiichi Sankyo Inc.$15
  • Abbott$15
  • Novo Nordisk$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$11090%
  • Education$1210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$121 in reported general payments places this provider in the 30th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$242,878
Medicare patients
825
Services billed
2,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$221,466
JardianceEmpagliflozin183$202,549
EliquisApixaban117$141,199
JanuviaSitagliptin Phosphate98$83,453
FarxigaDapagliflozin Propanediol39$57,025
JanumetSitagliptin Phos/Metformin Hcl34$39,960
XareltoRivaroxaban26$26,144
MounjaroTirzepatide24$25,218
WegovySemaglutide13$21,098
ProliaDenosumab11$18,616
Breo ElliptaFluticasone/Vilanterol18$15,884
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,853
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$10,673
Rosuvastatin Calcium680$8,988
MyrbetriqMirabegron11$8,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$14$242,564176 claims
GSKBreo Ellipta, Trelegy Ellipta$17$30,73737 claims
Lilly USA, LLCMounjaro$12$25,21824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Jamesburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →